Physician profile
Atinuke Aluko
NPI 1306366158
$41,195.03
in general payments reported to CMS, 2019-2025
12 companies · $533 in 2025
The $533 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.99 · 2020: $139 · 2021: $40K · 2022: $134 · 2023: $427 · 2024: $44.83 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976 · Education: $29.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.75 |
| Education | $29.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $39,878.04 | 2021-2023 | |
| Abbvie INC. | $636.93 | 2021-2025 | Rinvoq, Humira |
| Astrazeneca Pharmaceuticals LP | $147.94 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $103.24 | 2020-2025 | |
| Janssen Biotech, INC. | $99.00 | 2020 | |
| Genentech USA, INC. | $90.99 | 2019 | |
| Ucb, INC. | $75.17 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $58.87 | 2024-2025 | Enbrel, Tavneos, Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $29.60 | 2024 | Orencia |
| Aurinia Pharma U.S., INC. | $27.29 | 2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $26.93 | 2025 | Strensiq |
| Invivyd INC | $21.03 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atinuke Aluko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.